Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00590083 · ClinicalTrials.gov registry record · Phase 1
Administration of Virus-Specific Cytotoxic T-Lymphocytes
A Phase 1 study, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT00590083 is a Phase 1 study that has completed, run by Baylor College of Medicine. The registered enrollment target is 14 participants.
The verdict
NCT00590083, a Phase 1 study, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The main purpose of this study is to see if these T-lymphocytes are safe. To make these Ad-specific T lymphocytes the investigators will obtain blood from the stem cell donor and transfer Ad into another type of blood cell, called monocytes. These cells can then stimulate the T lymphocytes and train them to kill cells infected with Ad. The investigators will then grow these Ad-specific T lymphocytes by more stimulation with Ad-infected monocytes and a third type of blood cell called a B lymphoblast from the donor. After testing the T -lymphocytes, the investigators will inject them into patients after transplant who are at high risk of serious Ad virus infection. The investigators will make sure the injected cells are safe and see if they affect the growth and behavior of adenoviruses in the patient's own body.
Interventions
- BIOLOGICAL CTL administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2003-07 |
| Est. Completion | 2011-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00590083
The ClinicalTrials.gov registry entry for NCT00590083 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CTL administration is the first listed.
NCT00590083 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00590083 about?
NCT00590083 is a clinical study titled "Administration of Virus-Specific Cytotoxic T-Lymphocytes". The main purpose of this study is to see if these T-lymphocytes are safe. To make these Ad-specific T lymphocytes the investigators will obtain blood from the stem cell donor and transfer Ad into another type of blood cell, called monocytes. These cells can then stimulate the T lymphocytes and train...
What is the current status of trial NCT00590083?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2003-07. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00590083?
The interventions under investigation include: CTL administration (BIOLOGICAL).
Who is sponsoring clinical trial NCT00590083?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.